DownloadHi-Res Photo

Mitchell Clark, MD, MPH

Assistant Professor of Obstetrics, Gynecology & Reproductive Sciences; Director, Gynecologic Oncology at Waterford; Assistant Program Director, Minimally Invasive Gynecological Surgery Program; Associate Director, Center for Precision Diagnosis of Trophoblastic Disease

Contact Information

Email
mitchell.clark@yale.edu

Office Location

Obstetrics, Gynecology & Reproductive Sciences
Farnam Memorial Building
310 Cedar Street, Wing Gynecologic Oncology, Fl 3rd, Ste 328
New Haven, CT 06510
General Information:203.785.4013
Fax:203.785.4135

Mailing Address

Obstetrics, Gynecology & Reproductive Sciences
PO Box 208063
New Haven, CT 06520
United States

Patient Care

Are you a patient?Please visit the Yale Medicine website for information about the services we offer and making an appointment.View Doctor Profile

Research & Publications
Biography
News
Locations

Research Summary

My current research interests include investigating the role of surgery in ovarian cancer and understanding the relationship between timing of chemotherapy and wound healing on oncologic outcomes in high-risk ovarian cancer. Additionally, I am passionate about reducing the burden of cervical cancer in our population through the use of large healthcare administrative databases to identify populations at high risk and to increase screening and detection of pre-cancerous disease.

Coauthors

Selected Publications

Black-White differences in uterine cancer symptomatology and stage at diagnosisXu X, Chen L, Nunez-Smith M, Clark M, Ferris J, Hershman D, Wright J. Black-White differences in uterine cancer symptomatology and stage at diagnosis. Gynecologic Oncology 2023, 180: 118-125. PMID: 38091770, PMCID: PMC10922746, DOI: 10.1016/j.ygyno.2023.11.029.
ICG Fluorescence Technique for Detection of Sentinel Lymph Nodes in Laparoscopic Endometrial Cancer StagingAlAshqar A, Mutlu L, McNamara B, Harold J, Clark M, Huang G, Azodi M, Schwartz P, Santin A, Ratner E, Altwerger G, Andikyan V. ICG Fluorescence Technique for Detection of Sentinel Lymph Nodes in Laparoscopic Endometrial Cancer Staging. Journal Of Minimally Invasive Gynecology 2023, 30: s36. DOI: 10.1016/j.jmig.2023.08.110.
Timeliness of diagnostic evaluation for postmenopausal bleeding: A retrospective cohort study using claims dataXu X, Chen L, Nunez-Smith M, Clark M, Wright J. Timeliness of diagnostic evaluation for postmenopausal bleeding: A retrospective cohort study using claims data. PLOS ONE 2023, 18: e0289692. PMID: 37682914, PMCID: PMC10490884, DOI: 10.1371/journal.pone.0289692.
In Vivo and In Vitro Efficacy of Trastuzumab Deruxtecan in Uterine Serous Carcinoma.Mutlu L, Manavella D, Bellone S, McNamara B, Harold J, Mauricio D, Siegel E, Buza N, Hui P, Hartwich T, Yang-Hartwich Y, Demirkiran C, Verzosa M, Altwerger G, Ratner E, Huang G, Clark M, Andikyan V, Azodi M, Dottino P, Schwartz P, Santin A. In Vivo and In Vitro Efficacy of Trastuzumab Deruxtecan in Uterine Serous Carcinoma. Molecular Cancer Therapeutics 2023, 22: 1404-1412. PMID: 37676984, DOI: 10.1158/1535-7163.mct-23-0126.
Uterine Leiomyosarcomas harboring MAP2K4 gene amplification are markedly sensitive in vivo to PLX8725, a Novel MAP2K4 Inhibitor (1315)McNamara B, Harold J, Manavella D, Bellone S, Mutlu L, Hartwich T, Zipponi M, Yang-Hartwich Y, Demirkiran C, Verzosa M, Choi J, Dong W, Buza N, Hui P, Altwerger G, Huang G, Andikyan V, Clark M, Ratner E, Azodi M, Schwartz P, Schlessinger J, Santin A. Uterine Leiomyosarcomas harboring MAP2K4 gene amplification are markedly sensitive in vivo to PLX8725, a Novel MAP2K4 Inhibitor (1315). Gynecologic Oncology 2023, 176: s193. DOI: 10.1016/j.ygyno.2023.06.218.
Delayed presentation of placenta accreta following a first‐trimester medical abortionMaurer J, Ramani S, Xu B, Gallousis S, Clark M, Andikyan V. Delayed presentation of placenta accreta following a first‐trimester medical abortion. Clinical Case Reports 2023, 11: e7849. PMID: 37636882, PMCID: PMC10457480, DOI: 10.1002/ccr3.7849.
Hyperthermic Intraperitoneal Chemotherapy in Ovarian CancerGelissen J, Adjei N, McNamara B, Mutlu L, Harold J, Clark M, Altwerger G, Dottino P, Huang G, Santin A, Azodi M, Ratner E, Schwartz P, Andikyan V. Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer. Annals Of Surgical Oncology 2023, 30: 5597-5609. PMID: 37358686, DOI: 10.1245/s10434-023-13757-0.
Preliminary results of a phase II trial with sacituzumab govitecan-hziy in patients with recurrent endometrial carcinoma overexpressing Trop-2.Santin A, McNamara B, Siegel E, Harold J, Mutlu L, Altwerger G, Huang G, Andikyan V, Clark M, Ratner E, Azodi M, Dottino P, Schwartz P, Bellone S. Preliminary results of a phase II trial with sacituzumab govitecan-hziy in patients with recurrent endometrial carcinoma overexpressing Trop-2. Journal Of Clinical Oncology 2023, 41: 5599-5599. DOI: 10.1200/jco.2023.41.16_suppl.5599.
Abstract 3402: In vivo efficacy of RAF/MEK clamp avutometinib (VS-6766) in combination with FAK inhibition in low grade serous ovarian cancerMcNamara B, Demirkiran C, Bellone S, Mutlu L, Zipponi M, Verzosa M, Harold J, Hartwich T, Altwerger G, Ratner E, Huang G, Clark M, Andikyan V, Azodi M, Schwartz P, Dottino P, Santin A. Abstract 3402: In vivo efficacy of RAF/MEK clamp avutometinib (VS-6766) in combination with FAK inhibition in low grade serous ovarian cancer. Cancer Research 2023, 83: 3402-3402. DOI: 10.1158/1538-7445.am2023-3402.
Uterine leiomyosarcomas harboring MAP2K4 gene amplification are sensitive in vivo to PLX8725, a novel MAP2K4 inhibitorMcNamara B, Harold J, Manavella D, Bellone S, Mutlu L, Hartwich T, Zipponi M, Yang-Hartwich Y, Demirkiran C, Verzosa M, Yang K, Choi J, Dong W, Buza N, Hui P, Altwerger G, Huang G, Andikyan V, Clark M, Ratner E, Azodi M, Schwartz P, Burton E, Inagaki H, Albers A, Zhang C, Bollag G, Schlessinger J, Santin A. Uterine leiomyosarcomas harboring MAP2K4 gene amplification are sensitive in vivo to PLX8725, a novel MAP2K4 inhibitor. Gynecologic Oncology 2023, 172: 65-71. PMID: 36958197, PMCID: PMC10192120, DOI: 10.1016/j.ygyno.2023.03.009.
Corrigendum to “Elimusertib (BAY1895344), a novel ATR inhibitor, demonstrates in vivo activity in ATRX mutated models of uterine leiomyosarcoma”Harold J, Bellone S, Manavell D, Mutlu L, McNamara B, Hartwich T, Zipponi M, Yang-Hartwich Y, Demirkiran C, Verzosa M, Choi J, Dong W, Buza N, Hui P, Altwerger G, Huang G, Andikyan V, Clark M, Ratner E, Azodi M, Schwartz P, Santin A. Corrigendum to “Elimusertib (BAY1895344), a novel ATR inhibitor, demonstrates in vivo activity in ATRX mutated models of uterine leiomyosarcoma”. Gynecologic Oncology 2023, 170: 334. PMID: 36906375, PMCID: PMC10266020, DOI: 10.1016/j.ygyno.2023.01.029.
Changes to same day discharge after minimally invasive hysterectomy throughout COVID‐19 pandemicSullivan M, Michel L, Wasser T, Clark M, Chudnoff S, Andikyan V. Changes to same day discharge after minimally invasive hysterectomy throughout COVID‐19 pandemic. Journal Of Obstetrics And Gynaecology Research 2023, 49: 1418-1423. PMID: 36808793, DOI: 10.1111/jog.15617.
Racial disparities in diagnostic evaluation of uterine cancer among Medicaid beneficiaries.Xu X, Chen L, Nunez-Smith M, Clark M, Wright J. Racial disparities in diagnostic evaluation of uterine cancer among Medicaid beneficiaries. Journal Of The National Cancer Institute 2023, 115: 636-643. PMID: 36788453, PMCID: PMC10248843, DOI: 10.1093/jnci/djad027.
The Poly (ADP-ribose) polymerase inhibitor olaparib and pan-ErbB inhibitor neratinib are highly synergistic in HER2 overexpressing epithelial ovarian carcinoma in vitro and in vivoHan C, McNamara B, Bellone S, Harold J, Manara P, Hartwich T, Mutlu L, Yang-Hartwich Y, Zipponi M, Demirkiran C, Verzosa M, Altwerger G, Ratner E, Huang G, Clark M, Andikyan V, Azodi M, Dottino P, Schwartz P, Santin A. The Poly (ADP-ribose) polymerase inhibitor olaparib and pan-ErbB inhibitor neratinib are highly synergistic in HER2 overexpressing epithelial ovarian carcinoma in vitro and in vivo. Gynecologic Oncology 2023, 170: 172-178. PMID: 36706643, PMCID: PMC10023457, DOI: 10.1016/j.ygyno.2023.01.015.
Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody–drug conjugate with topoisomerase I inhibitor payload, shows antitumor activity in uterine and ovarian carcinosarcoma with HER2/neu expressionMauricio D, Bellone S, Mutlu L, McNamara B, Manavella D, Demirkiran C, Verzosa M, Buza N, Hui P, Hartwich T, Harold J, Yang-Hartwich Y, Zipponi M, Altwerger G, Ratner E, Huang G, Clark M, Andikyan V, Azodi M, Schwartz P, Santin A. Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody–drug conjugate with topoisomerase I inhibitor payload, shows antitumor activity in uterine and ovarian carcinosarcoma with HER2/neu expression. Gynecologic Oncology 2023, 170: 38-45. PMID: 36610380, PMCID: PMC10445234, DOI: 10.1016/j.ygyno.2022.12.018.
Carbon Dioxide Emissions and Environmental Impact of Different Surgical Modalities of Hysterectomies.Ramani S, Hartnett J, Karki S, Gallousis S, Clark M, Andikyan V. Carbon Dioxide Emissions and Environmental Impact of Different Surgical Modalities of Hysterectomies. JSLS Journal Of The Society Of Laparoscopic & Robotic Surgeons 2023, 27: e2023.00021. PMID: 37663433, PMCID: PMC10473183, DOI: 10.4293/jsls.2023.00021.
Ovarian and uterine carcinosarcomas are sensitive in vitro and in vivo to elimusertib, a novel ataxia-telangiectasia and Rad3-related (ATR) kinase inhibitorManavella D, McNamara B, Harold J, Bellone S, Hartwich T, Yang-Hartwich Y, Mutlu L, Zipponi M, Demirkiran C, Verzosa M, Altwerger G, Ratner E, Huang G, Clark M, Andikyan V, Azodi M, Schwartz P, Dottino P, Choi J, Alexandrov L, Buza N, Hui P, Santin A. Ovarian and uterine carcinosarcomas are sensitive in vitro and in vivo to elimusertib, a novel ataxia-telangiectasia and Rad3-related (ATR) kinase inhibitor. Gynecologic Oncology 2022, 169: 98-105. PMID: 36525930, PMCID: PMC9925406, DOI: 10.1016/j.ygyno.2022.12.003.
EP007/#994 Bay 1895344, a novel ATR inhibitor, demonstrates in vivo activity against ATRX altered uterine leiomyosarcomaHarold J, Manavella D, Bellone S, Siegel E, Hartwich T, Zammataro L, Mutlu L, Altwerger G, Menderes G, Ratner E, Huang G, Clark M, Andikyan V, Azodi M, Schwartz P, Alexandrov L, Santin A. EP007/#994 Bay 1895344, a novel ATR inhibitor, demonstrates in vivo activity against ATRX altered uterine leiomyosarcoma. 2022, a51.1-a51. DOI: 10.1136/ijgc-2022-igcs.98.
Elimusertib (BAY1895344), a novel ATR inhibitor, demonstrates in vivo activity in ATRX mutated models of uterine leiomyosarcomaHarold J, Bellone S, Manavella D, Mutlu L, McNamara B, Hartwich T, Zipponi M, Yang-Hartwich Y, Demirkiran C, Verzosa M, Choi J, Dong W, Buza N, Hui P, Altwerger G, Huang G, Andikyan V, Clark M, Ratner E, Azodi M, Schwartz P, Santin A. Elimusertib (BAY1895344), a novel ATR inhibitor, demonstrates in vivo activity in ATRX mutated models of uterine leiomyosarcoma. Gynecologic Oncology 2022, 168: 157-165. PMID: 36442427, PMCID: PMC9797429, DOI: 10.1016/j.ygyno.2022.11.014.
Validation of the KELIM score as a predictor of response to neoadjuvant treatment in patients with advanced high grade serous ovarian cancerPiedimonte S, Kim R, Bernardini M, Atenafu E, Clark M, Lheureux S, May T. Validation of the KELIM score as a predictor of response to neoadjuvant treatment in patients with advanced high grade serous ovarian cancer. Gynecologic Oncology 2022, 167: 417-422. PMID: 37191644, DOI: 10.1016/j.ygyno.2022.10.014.
The modeled CA-125 elimination rate constant k (KELIM) score as a predictor of treatment response in patients with advanced high grade serous ovarian cancer (190)Piedimonte S, Kim S, Clark M, Lheureux S, May T, Bernardini M, Atenafu E. The modeled CA-125 elimination rate constant k (KELIM) score as a predictor of treatment response in patients with advanced high grade serous ovarian cancer (190). Gynecologic Oncology 2022, 166: s109. DOI: 10.1016/s0090-8258(22)01417-2.
In Vivo and In Vitro Efficacy of Enhertu in Uterine Serous Carcinoma (047)Mutlu L, Manavella D, Bellone S, Harold J, Mauricio D, Tymon-Rosario J, Siegel E, Hartwich T, Altwerger G, Menderes G, Ratner E, Huang G, Clark M, Andikyan V, Azodi M, Schwartz P, Santin A. In Vivo and In Vitro Efficacy of Enhertu in Uterine Serous Carcinoma (047). Gynecologic Oncology 2022, 166: s32-s33. DOI: 10.1016/s0090-8258(22)01266-5.
Homologous recombination deficiency (HRD) signature-3 in ovarian and uterine carcinosarcomas correlates with preclinical sensitivity to Olaparib, a Poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitor (043)Tymon-Rosario J, Manara P, Manavella D, Bellone S, Siegel E, Hartwich T, Harold J, Zammataro L, Yang-Hartwich Y, Mutlu L, Altwerger G, Menderes G, Ratner E, Huang G, Clark M, Andikyan V, Azodi M, Schwartz P, Alexandrov L, Santin A. Homologous recombination deficiency (HRD) signature-3 in ovarian and uterine carcinosarcomas correlates with preclinical sensitivity to Olaparib, a Poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitor (043). Gynecologic Oncology 2022, 166: s30. DOI: 10.1016/s0090-8258(22)01262-8.
Ovarian and uterine carcinosarcoma cell lines show preclinical sensitivity to BAY 1895344, a novel ataxia-telangiectasia and Rad3-related (ATR) kinase inhibitor (011)Manavella D, Harold J, Bellone S, Hartwich T, Mutlu L, Tymon-Rosario J, Siegel E, Altwerger G, Menderes G, Ratner E, Huang G, Clark M, Andikyan V, Azodi M, Schwartz P, Alexandrov L, Santin A. Ovarian and uterine carcinosarcoma cell lines show preclinical sensitivity to BAY 1895344, a novel ataxia-telangiectasia and Rad3-related (ATR) kinase inhibitor (011). Gynecologic Oncology 2022, 166: s9. DOI: 10.1016/s0090-8258(22)01229-x.
Trastuzumab deruxtecan (DS-8201a), a HER2-Targeting Antibody-Drug Conjugate with Topoisomerase I Inhibitor Payload, Shows Antitumor Activity in Uterine and Ovarian Carcinosarcoma with HER2/neu Expression (046)Mauricio D, Bellone S, Manavella D, Harold J, Buza N, Altwerger G, Menderes G, Ratner E, Huang G, Clark M, Andikyan V, Azodi M, Schwartz P, Santin A. Trastuzumab deruxtecan (DS-8201a), a HER2-Targeting Antibody-Drug Conjugate with Topoisomerase I Inhibitor Payload, Shows Antitumor Activity in Uterine and Ovarian Carcinosarcoma with HER2/neu Expression (046). Gynecologic Oncology 2022, 166: s31-s32. DOI: 10.1016/s0090-8258(22)01265-3.
BAY1895344, a novel ataxia telangiectasia and RAD3-related (ATR) inhibitor, is active in vivo against ATRX mutated uterine leiomyosarcoma (212)Harold J, Manavella D, Bellone S, Siegel E, Mauricio D, Hartwich T, Zammataro L, Mutlu L, AlAshqar A, Altwerger G, Menderes G, Ratner E, Huang G, Clark M, Andikyan V, Azodi M, Schwartz P, Alexandrov L, Santin A. BAY1895344, a novel ataxia telangiectasia and RAD3-related (ATR) inhibitor, is active in vivo against ATRX mutated uterine leiomyosarcoma (212). Gynecologic Oncology 2022, 166: s118. DOI: 10.1016/s0090-8258(22)01437-8.
A phase 2 evaluation of pembrolizumab for recurrent Lynch‐like versus sporadic endometrial cancers with microsatellite instabilityBellone S, Roque DM, Siegel ER, Buza N, Hui P, Bonazzoli E, Guglielmi A, Zammataro L, Nagarkatti N, Zaidi S, Lee J, Silasi D, Huang GS, Andikyan V, Damast S, Clark M, Azodi M, Schwartz PE, Tymon‐Rosario J, Harold JA, Mauricio D, Zeybek B, Menderes G, Altwerger G, Ratner E, Alexandrov LB, Iwasaki A, Kong Y, Song E, Dong W, Elvin JA, Choi J, Santin AD. A phase 2 evaluation of pembrolizumab for recurrent Lynch‐like versus sporadic endometrial cancers with microsatellite instability. Cancer 2021, 128: 1206-1218. PMID: 34875107, PMCID: PMC9465822, DOI: 10.1002/cncr.34025.
Two-Port Robotic Laparoscopic HysterectomyMauricio D, Webster E, Harold J, Altwerger G, Azodi M, Clark M, Huang G, Menderes G, Ratner E, Santin A, Schwartz P, Andikyan V. Two-Port Robotic Laparoscopic Hysterectomy. Journal Of Minimally Invasive Gynecology 2021, 28: s155. DOI: 10.1016/j.jmig.2021.09.315.
Placenta increta mimicking placental site trophoblastic tumor.Clark M, Tchrakian N, Clarke B, Metser U, Bouchard-Fortier G. Placenta increta mimicking placental site trophoblastic tumor. International Journal Of Gynecological Cancer : Official Journal Of The International Gynecological Cancer Society 2021, 31: 1481-1485. PMID: 34725244, DOI: 10.1136/ijgc-2021-002988.
In vitro and in vivo activity of DHES0815A, an antibody-drug conjugate targeting HER2/neu in uterine serous carcinomaTymon-Rosario J, Bonazzoli E, Guglielmi A, Bellone S, Nagarkatti N, Zammataro L, Zeybek B, Harold J, Mauricio D, Clark M, Andikyan V, Huang G, Altwerger G, Menderes G, Azodi M, Ratner E, Schwartz P, Santin A. In vitro and in vivo activity of DHES0815A, an antibody-drug conjugate targeting HER2/neu in uterine serous carcinoma. Gynecologic Oncology 2021, 162: s186-s187. DOI: 10.1016/s0090-8258(21)01001-5.
Financial toxicity in patients with gynecologic malignanciesZeybek B, Webster E, Pogosian N, Tymon-Rosario J, Mauricio D, Harold J, Menderes G, Altwerger G, Malette J, Luther M, Baker L, Balch A, Clark M, Huang G, Azodi M, Ratner E, Schwartz P, Santin A, Andikyan V. Financial toxicity in patients with gynecologic malignancies. Gynecologic Oncology 2021, 162: s162. DOI: 10.1016/s0090-8258(21)00950-1.
Charlson Comorbidity Index as a predictor of postoperative complication in octogenarians and nonagenarians with stage I endometrioid endometrial cancer: a single-institution retrospective reviewWebster E, Arkfeld C, Chang Y, Yadav G, Zeybek B, Tymon-Rosario J, Harold J, Clark M, Andikyan V, Huang G, Menderes G, Azodi M, Santin A, Schwartz P, Ratner E, Altwerger G. Charlson Comorbidity Index as a predictor of postoperative complication in octogenarians and nonagenarians with stage I endometrioid endometrial cancer: a single-institution retrospective review. Gynecologic Oncology 2021, 162: s108. DOI: 10.1016/s0090-8258(21)00848-9.
Randomized phase II trial of weekly ixabepilone with or without biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancerRoque D, Siegel E, Buza N, Bellone S, Silasi D, Huang G, Andikyan V, Clark M, Azodi M, Schwartz P, Rao G, Reader J, Hui P, Tymon-Rosario J, Harold J, Mauricio D, Zeybek B, Menderes G, Altwerger G, Ratner E, Santin A. Randomized phase II trial of weekly ixabepilone with or without biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer. Gynecologic Oncology 2021, 162: s58. DOI: 10.1016/s0090-8258(21)00753-8.
The impact of a universal human papilloma virus (HPV) vaccination program on lower genital tract dysplasia and genital wartsClark M, Jembere N, Kupets R. The impact of a universal human papilloma virus (HPV) vaccination program on lower genital tract dysplasia and genital warts. Preventive Medicine 2021, 150: 106641. PMID: 34048822, DOI: 10.1016/j.ypmed.2021.106641.
Endometrial Carcinoma as the Presenting Malignancy in a Teenager With a Pathogenic TP53 Germline Mutation: A Case Report and Literature ReviewIrshaid L, Clark M, Fadare O, Finberg KE, Parkash V. Endometrial Carcinoma as the Presenting Malignancy in a Teenager With a Pathogenic TP53 Germline Mutation: A Case Report and Literature Review. International Journal Of Gynecological Pathology 2021, 41: 258-267. PMID: 33990091, DOI: 10.1097/pgp.0000000000000792.
Integrated mutational landscape analysis of uterine leiomyosarcomasChoi J, Manzano A, Dong W, Bellone S, Bonazzoli E, Zammataro L, Yao X, Deshpande A, Zaidi S, Guglielmi A, Gnutti B, Nagarkatti N, Tymon-Rosario JR, Harold J, Mauricio D, Zeybek B, Menderes G, Altwerger G, Jeong K, Zhao S, Buza N, Hui P, Ravaggi A, Bignotti E, Romani C, Todeschini P, Zanotti L, Odicino F, Pecorelli S, Ardighieri L, Bilguvar K, Quick CM, Silasi DA, Huang GS, Andikyan V, Clark M, Ratner E, Azodi M, Imielinski M, Schwartz PE, Alexandrov LB, Lifton RP, Schlessinger J, Santin AD. Integrated mutational landscape analysis of uterine leiomyosarcomas. Proceedings Of The National Academy Of Sciences Of The United States Of America 2021, 118: e2025182118. PMID: 33876771, PMCID: PMC8053980, DOI: 10.1073/pnas.2025182118.
Survival of Older Women With Cervical Cancer Based on Screening History.Clark M, Jembere N, Wang L, Kupets R. Survival of Older Women With Cervical Cancer Based on Screening History. Journal Of Lower Genital Tract Disease 2021, 25: 9-14. PMID: 33347044, DOI: 10.1097/lgt.0000000000000582.
The impact of a universal HPV vaccination program on lower genital tract dysplasia and genital wartsClark M, Jembere N, Kupets R. The impact of a universal HPV vaccination program on lower genital tract dysplasia and genital warts. Gynecologic Oncology 2020, 159: 173. DOI: 10.1016/j.ygyno.2020.05.257.
Is there a benefit to the lowest possible CA-125: The relationship between biomarkers and survival in epithelial ovarian cancerClark M, houssan L, Liu Z, Bernardini M. Is there a benefit to the lowest possible CA-125: The relationship between biomarkers and survival in epithelial ovarian cancer. Gynecologic Oncology 2019, 154: 261. DOI: 10.1016/j.ygyno.2019.04.603.
Resuming chemotherapy after interval cytoreductive surgery in ovarian cancer: The impact of time and temperatureClark M, Kollara A, May T, Brown T. Resuming chemotherapy after interval cytoreductive surgery in ovarian cancer: The impact of time and temperature. Gynecologic Oncology 2019, 154: 55-56. DOI: 10.1016/j.ygyno.2019.04.133.
Limitations in Correspondence Programs for Cervical Cancer Screening: Who Are the Women We Are Missing?Clark M, Lee A, Kupets R. Limitations in Correspondence Programs for Cervical Cancer Screening: Who Are the Women We Are Missing? Journal Of Obstetrics And Gynaecology Canada 2019, 41: 1410-1415. PMID: 30803876, DOI: 10.1016/j.jogc.2018.11.034.
Pseudovascular Invasion: Minimally Invasive Surgery for Endometrial CancerSeifi F, Parkash V, Clark M, Menderes G, Tierney C, Silasi DA, Azodi M. Pseudovascular Invasion: Minimally Invasive Surgery for Endometrial Cancer. JSLS Journal Of The Society Of Laparoscopic & Robotic Surgeons 2019, 23: e2019.00021. PMID: 31285650, PMCID: PMC6596444, DOI: 10.4293/jsls.2019.00021.
500 Does Use of Manipulator for Endometrial Cancer Surgery Lead to Increased Use of Adjuvant Therapy?Seifi F, Clark M, Menderes G, Silasi D, Azodi M. 500 Does Use of Manipulator for Endometrial Cancer Surgery Lead to Increased Use of Adjuvant Therapy? Journal Of Minimally Invasive Gynecology 2018, 25: s175. DOI: 10.1016/j.jmig.2018.09.512.
Does the use of manipulator for endometrial cancer surgery lead to increased use of adjuvant therapy?Clark M, Seifi F, Parkash V, Silasi D, Azodi M. Does the use of manipulator for endometrial cancer surgery lead to increased use of adjuvant therapy? Gynecologic Oncology 2018, 149: 93. DOI: 10.1016/j.ygyno.2018.04.213.
Does the time interval off neoadjuvant chemotherapy before and after interval debulking surgery affect the overall survival of women with advanced-epithelial ovarian cancer?Clark M, Lee Y, Xu W, Brown T, May T. Does the time interval off neoadjuvant chemotherapy before and after interval debulking surgery affect the overall survival of women with advanced-epithelial ovarian cancer? Gynecologic Oncology 2018, 149: 92. DOI: 10.1016/j.ygyno.2018.04.210.
Investigating the time intervals between primary cytoreductive surgery and initiation of adjuvant chemotherapy in patients with advanced epithelial ovarian cancer who had optimal cytoreduction surgery with bowel resectionLee Y, Lee J, Paik E, Clark M, Kim R, Brown T, May T. Investigating the time intervals between primary cytoreductive surgery and initiation of adjuvant chemotherapy in patients with advanced epithelial ovarian cancer who had optimal cytoreduction surgery with bowel resection. Gynecologic Oncology 2018, 149: 98. DOI: 10.1016/j.ygyno.2018.04.226.
Clinical stage II endometrial cancer: Is there a benefit to radical hysterectomy?Lennox G, Clark M, Zigras T, Rouzbahman M, Han G, Bernardini M, Gien L. Clinical stage II endometrial cancer: Is there a benefit to radical hysterectomy? Gynecologic Oncology 2018, 149: 103. DOI: 10.1016/j.ygyno.2018.04.239.
Cancer screening correspondence coverage in Ontario, Canada: Factors related to limitations in reachClark M, Lee A, Kupets R. Cancer screening correspondence coverage in Ontario, Canada: Factors related to limitations in reach. Gynecologic Oncology 2018, 149: 126-127. DOI: 10.1016/j.ygyno.2018.04.292.
563 Robatic Tumor Debulking with Partial Cystectomy, Bladder Reconstruction, and Ureteral Implantation in Recurrent Endometrial CancerSeifi F, Davis M, Clark M, Paraiso E, Azodi M. 563 Robatic Tumor Debulking with Partial Cystectomy, Bladder Reconstruction, and Ureteral Implantation in Recurrent Endometrial Cancer. Journal Of Minimally Invasive Gynecology 2017, 24: s184-s185. DOI: 10.1016/j.jmig.2017.08.591.
519 Recurrent Endometrial Cancer : Robotic-Assisted Laparoscopy, Debulking of Tumor with Dense Adhesion to Iliac Vessels, Involving Upper Vagina and Ureterovesical JunctionSeifi F, Clark M, Sami A, Azodi M. 519 Recurrent Endometrial Cancer : Robotic-Assisted Laparoscopy, Debulking of Tumor with Dense Adhesion to Iliac Vessels, Involving Upper Vagina and Ureterovesical Junction. Journal Of Minimally Invasive Gynecology 2017, 24: s183. DOI: 10.1016/j.jmig.2017.08.547.
Dual-Targeting Nanoparticles for In Vivo Delivery of Suicide Genes to Chemotherapy-Resistant Ovarian Cancer CellsCocco E, Deng Y, Shapiro EM, Bortolomai I, Lopez S, Lin K, Bellone S, Cui J, Menderes G, Black JD, Schwab CL, Bonazzoli E, Yang F, Predolini F, Zammataro L, Altwerger G, de Haydu C, Clark M, Alvarenga J, Ratner E, Azodi M, Silasi DA, Schwartz PE, Litkouhi B, Saltzman WM, Santin AD. Dual-Targeting Nanoparticles for In Vivo Delivery of Suicide Genes to Chemotherapy-Resistant Ovarian Cancer Cells. Molecular Cancer Therapeutics 2017, 16: 323-333. PMID: 27956521, PMCID: PMC5292071, DOI: 10.1158/1535-7163.mct-16-0501.
Endometrial carcinoma as the presenting malignancy in an 18-year-old patient with Li-Fraumeni syndromeClark M, Menderes G, Azodi M, Finberg K, Canosa S, Parkash V. Endometrial carcinoma as the presenting malignancy in an 18-year-old patient with Li-Fraumeni syndrome. Gynecologic Oncology 2016, 141: 183-184. DOI: 10.1016/j.ygyno.2016.04.473.
Novel targeted therapies in uterine serous carcinoma, an aggressive variant of endometrial cancer.Menderes G, Clark M, Santin AD. Novel targeted therapies in uterine serous carcinoma, an aggressive variant of endometrial cancer. Discovery Medicine 2016, 21: 293-303. PMID: 27232515.
Uterine Serous Carcinoma: Does surgical approach impact survival?Clark M, Glasgow M, Menderes G, Azodi M, Silasi D. Uterine Serous Carcinoma: Does surgical approach impact survival? Gynecologic Oncology 2015, 139: 592. DOI: 10.1016/j.ygyno.2015.09.045.
Early Stage Uterine Serous Carcinoma: Does Surgical Approach Impact Survival?Clark M, Glasgow M, Menderes G, Azodi M, Silasi DA. Early Stage Uterine Serous Carcinoma: Does Surgical Approach Impact Survival? Journal Of Minimally Invasive Gynecology 2015, 22: s48-s49. PMID: 27679256, DOI: 10.1016/j.jmig.2015.08.134.
Identifying Risk Factors for Urinar y Retention After Hysterectomy for LeiomyomaClark Donat L, Tower A, Clark M, Silasi DA, Azodi M. Identifying Risk Factors for Urinar y Retention After Hysterectomy for Leiomyoma. Journal Of Minimally Invasive Gynecology 2015, 22: s59. PMID: 27679285, DOI: 10.1016/j.jmig.2015.08.157.
Minimally Invasive Non-Laparoscopic Ovarian Cystectomy: A Unique Way to Approach Large Ovarian CystsClark M, Zigras T, Bayat L, Kashani S. Minimally Invasive Non-Laparoscopic Ovarian Cystectomy: A Unique Way to Approach Large Ovarian Cysts. Journal Of Minimally Invasive Gynecology 2015, 22: s150. PMID: 27678844, DOI: 10.1016/j.jmig.2015.08.547.
Transvaginal MorcellationDonat L, Clark M, Tower AM, Menderes G, Parkash V, Silasi DA, Azodi M. Transvaginal Morcellation. JSLS Journal Of The Society Of Laparoscopic & Robotic Surgeons 2015, 19: e2014.00255. PMID: 26005318, PMCID: PMC4432719, DOI: 10.4293/jsls.2014.00255.
Rupture of the Unscarred Gravid Uterus: Case SeriesO’Sullivan R, Sauer C, Friedman P, Clark M, Menderes G. Rupture of the Unscarred Gravid Uterus: Case Series. Journal Of Medical Cases 2015, 6: 330-332. DOI: 10.14740/jmc2203w.
Risk Factors Associated with Urinary Retention after Robotic-Assisted Laparoscopic HysterectomyClark L, Clark M, Menderes G, Silasi D, Azodi M. Risk Factors Associated with Urinary Retention after Robotic-Assisted Laparoscopic Hysterectomy. Journal Of Minimally Invasive Gynecology 2014, 21: s205. DOI: 10.1016/j.jmig.2014.08.658.

Edit Profile

Contact Information

Office Location

Mailing Address

Related Links

Patient Care

Research & Publications

Biography

News

Locations

Research Summary

Coauthors

Selected Publications